Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Preferred Stock Liabilities (2019)

Historic Preferred Stock Liabilities for Beam Therapeutics (BEAM) over the last 1 years, with Q4 2019 value amounting to $302.0 million.

  • Beam Therapeutics' Preferred Stock Liabilities changed N/A to $302.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $302.0 million, marking a year-over-year change of. This contributed to the annual value of $302.0 million for FY2019, which is N/A changed from last year.
  • Beam Therapeutics' Preferred Stock Liabilities amounted to $302.0 million in Q4 2019.
  • Beam Therapeutics' 5-year Preferred Stock Liabilities high stood at $302.0 million for Q4 2019, and its period low was $292.3 million during Q1 2019.